港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表

智通财经
Mar 26

智通财经APP获悉,轩竹生物-B(02575)早盘涨超18%,截至发稿,涨11.85%,报40.58港元,成交额1886.4万港元。

消息面上,3月24日,轩竹生物-B发布公告,公司自主研发的新型CDK2/4/6抑制剂吡洛西利(Bireociclib)的III期BRIGHT-2临床研究最终分析结果,已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》(JAMA Oncology,医学1区,影响因子20.1)正式在线全文发表。

BRIGHT-2研究是一项在中国开展的随机、双盲、安慰剂对照、多中心III期临床试验,旨在评估吡洛西利联合氟维司群在既往内分泌治疗进展后的激素受体阳性(HR+)、人类表皮生长因子受体2阴 性(HER2-)(HR+/HER2-)晚期乳腺癌患者中的疗效与安全性。本研究由中国医学科学院肿瘤医院徐兵河院士牵头,在全国64家医院开展。

公司曾于2025年4月在《Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。本次发表的为最终分析结果,在中期分析的基础上增加额外11个月的观察期,中位随访时间已延长至19个月,进一步揭示了吡洛西利在生存获益上的成熟度与稳健性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10